Results 71 to 80 of about 1,940,460 (362)

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

Emerging Therapies in Immune Thrombocytopenia

Journal of Clinical Medicine, 2021
Immune thrombocytopenia (ITP) is a rare autoimmune disorder caused by peripheral platelet destruction and inappropriate bone marrow production. The management of ITP is based on the utilization of steroids, intravenous immunoglobulins, rituximab ...
S. Audia, B. Bonnotte
semanticscholar   +1 more source

Anionic Citrate‐Based 3D‐Printed Scaffolds for Tunable and Sustained Orthobiologic Delivery to Enhance Tissue Regeneration

Advanced Functional Materials, EarlyView.
A potent anionic citric acid‐based 3D‐printed scaffold is developed for the sustained and controlled release of orthobiologics to enhance orthopedic therapeutic efficacy. Comprehensive in vivo studies demonstrated effective bone fusion and high safety at a low dose of BMP‐2 delivered by the system, establishing it as a promising platform for safe ...
Se‐Hwan Lee, Ruqiang Lu, Andrew House, Zizhao Li, Lindsey Hammond Burton, Katie Josephine Sikes, Lynn Marie Pezzanite, Drew William Koch, Kevin Michael Labus, Ben Gadomski, Jeremiah Easley, Richard Tuan Tran, Su Chin Heo   +12 more
wiley   +1 more source

Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation

Advanced Science, EarlyView.
Native thioredoxin‐1 (TRX) stimulates proliferation and rescues stem cells and cancer cells from multiple stressors by suppressing p53 and inhibiting ferroptosis via GPX4/SLC7A11 upregulation mediated by enhanced KLF4 expression and p53 promoter binding.
Jian Wu, Xiaobei Wang, Parker Mathews, Shaima Jabbar, Min Zhang, Haim Moskowitz, Wei Duan, David P. Nichols, George William Schaaf, John D. Olson, Andrew N. Macintyre, J. Daniel Bourland, Ivan Spasojevic, Jen‐Tsan Ashley Chi, Joel Ross, Nelson Chao, J. Mark Cline, Peter B. Heifetz, Yubin Kang   +18 more
wiley   +1 more source

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Blood Advances, 2020
Primary immune thrombocytopenia (ITP) is a predominantly immunoglobulin G (IgG)-autoantibody-mediated disease characterized by isolated thrombocytopenia.
T. Robak, M. Kaźmierczak, I. Jarque, V. Musteata, J. Treliński, N. Cooper, P. Kiessling, Ute Massow, F. Woltering, R. Snipes, Juan Ke, G. Langdon, J. Bussel, S. Jolles   +13 more
semanticscholar   +1 more source

Emerging Concepts in Immune Thrombocytopenia [PDF]

Frontiers in Immunology, 2018
Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts which presents with an increased bleeding risk. Several genetic risk factors (e.g., polymorphisms in immunity-related genes) predispose to ITP. Autoantibodies and cytotoxic CD8+ T cells (Tc) mediate the anti-platelet response leading to thrombocytopenia. Both effector
Maurice Swinkels, Maaike Rijkers, Jan Voorberg, Gestur Vidarsson, Frank W. G. Leebeek, A. J. Gerard Jansen, A. J. Gerard Jansen   +6 more
openaire   +3 more sources

Investigation into the Pancreatic Pathogenesis of SFTSV across Multiple Levels

Advanced Science, EarlyView.
A retrospective analysis revealed that 17.6% of severe fever with thrombocytopenia syndrome (SFTS) patients met the diagnostic criteria for clinically confirmed pancreatitis. Using human pancreatic organoids and murine models demonstrated that SFTSV exhibits a specific pancreatic tropism, leading to cell death and initiating a strong inflammatory ...
Xiaohan Liu, Zhihao Xu, Yilun Tong, Changtai Wang, Yueqi Yao, Yujie Diao, Jingyuan Ma, Shijun Zhou, Yinan Du, Zhenhua Zhang, Gang Xu   +10 more
wiley   +1 more source

T cell–mediated autoimmunity in immune thrombocytopenia

European Journal of Haematology, 2021
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and an increased risk of bleeding. In addition to anti‐platelet autoantibodies, CD8+ T cells have been implicated as a mechanism of platelet destruction.
J. Vrbensky, I. Nazy, Rumi Clare, M. Larché, D. Arnold   +4 more
semanticscholar   +1 more source

Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO‐01)

Annals of Gastroenterological Surgery, EarlyView.
Our aim was to compare the outcomes of preoperative chemotherapy with postoperative chemotherapy in patients with resectable colorectal liver metastases treated with CAPOX‐Bev. We demonstrated that both preoperative and postoperative CAPOX‐Bev were safely administered, and preoperative chemotherapy showed a numerically higher treatment compliance rate ...
Yuji Takakura, Katsunori Shinozaki, Satoshi Ikeda, Hiroyuki Egi, Yuzo Hirata, Manabu Shimomura, Takafumi Oshiro, Takao Hinoi, Daisuke Sumitani, Masahiro Nakahara, Masanori Yoshimitsu, Naruhiko Honmyo, Tsuyoshi Kobayashi, Junko Tanaka, Hideki Ohdan, on behalf of the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)   +15 more
wiley   +1 more source

A likely unavoidable clinical scenario during treatment for venous thromboembolism complicated with severe immune thrombocytopenia: A case report

Clinical Case Reports, 2021
Patients with immune thrombocytopenia have increased risks of bleeding and thrombosis. The acute‐phase treatment for venous thromboembolism complicated with severe immune thrombocytopenia involves a “platelet dilemma” in therapeutic decision‐making.
Takaya Takeuchi, Yunosuke Matsuura, Yoshimasa Yamamura, Momoko Ohkusu, Shohei Koyama, Takeshi Kawaguchi, Mayumi Akaki Nagayasu, Hiroyuki Komatsu, Akihiko Okayama, Tetsunori Ishikawa, Tatsuya Atsumi, Kazuo Kitamura   +11 more
doaj   +1 more source